The global dried blood spot collection cards market size is expected to reach at USD 527.10 million in 2030 and is projected to grow at a CAGR of 4.73% from 2025 to 2030. Dried blood spot (DBS) collection cards are used to diagnose infectious diseases, particularly in resource-constrained areas, or to screen newborns for inherited metabolic problems, with a range of novel and innovative DBS uses only lately emerging.
Growing research studies for DBS testing and its advantages for diagnostic purposes are expected to fuel the market growth during the forecast period. In addition, the WHO recently recommended dried blood spot collection cards for diagnosis of HIV and hepatitis B & C due to the benefits of DBS in collecting blood and transport.
Moreover, dried blood spot collection cards have been used in a variety of toxicology applications, including toxicokinetics, epidemiological, environmental, and forensic toxicology. Dried blood spot collection cards are anticipated to be used as a sample preparation approach in forensic toxicology, and they can cost-effectively retain evidence for closed cases. Screening procedures as well as follow-up of markers of clinical or forensic interest are further toxicological applications where these cards may be progressively utilized.
Developing economies in Africa and Asia have the highest prevalence of rabies. The detection and surveillance of such diseases are hampered by the absence of clinical laboratories. Through dried blood spot collection cards, rabies can be diagnosed with limited resources. As per the data published by the Australian Trade and Investment Commission, Australia has become home to a thriving network of more than 470 biotechnology companies. A high number of established biotechnology and pharmaceutical players and extensive R&D initiatives being undertaken by them are expected to create a high need for DBS testing for therapeutic drug monitoring applications.
Various international organizations such as the U.S. Food and Drug Administration and the World Health Organization acknowledge the role of DBS cards in this pandemic. For instance, In June 2021, Symbiotic, Inc. was granted EUA by the FDA for a COVID-19 self-collect antibody test. This test can be conducted using ELISA with DBS for detecting COVID-19 antibodies in individuals aged 18 years and older, with collecting the sample in children aged 5 years and older by an adult.
The increase in the adoption of dried blood spot collection cards for therapeutic drug monitoring is a major factor expected to boost market growth in the near future. For instance, in July 2022, a study was conducted by researchers from the University of Washington and Med Biotech Laboratories to assess the feasibility of at-home dried blood spot collection along with PCR as a technique for malaria research. The study is anticipated to impact the therapeutic drug and vaccine studies for malaria. Researchers concluded that at-home dried blood spot collection cards for PCR are acceptable, robust, and feasible techniques.
On the other hand, it has been observed that dried blood spot collection cards are susceptible to cross-contamination or contamination by users, the environment, the equipment, and other collection cards during sample processing. The majority of these concerns can be mitigated by proper care and handling. Prolonged air drying of the conventional dried blood spot collection cards and contamination between samples during blood collection are some major causes of a high proportion of reactive samples.
Growing research studies for DBS testing and its advantages for diagnostic purposes are expected to fuel the market growth during the forecast period. In addition, the WHO recently recommended dried blood spot collection cards for diagnosis of HIV and hepatitis B & C due to the benefits of DBS in collecting blood and transport.
Moreover, dried blood spot collection cards have been used in a variety of toxicology applications, including toxicokinetics, epidemiological, environmental, and forensic toxicology. Dried blood spot collection cards are anticipated to be used as a sample preparation approach in forensic toxicology, and they can cost-effectively retain evidence for closed cases. Screening procedures as well as follow-up of markers of clinical or forensic interest are further toxicological applications where these cards may be progressively utilized.
Developing economies in Africa and Asia have the highest prevalence of rabies. The detection and surveillance of such diseases are hampered by the absence of clinical laboratories. Through dried blood spot collection cards, rabies can be diagnosed with limited resources. As per the data published by the Australian Trade and Investment Commission, Australia has become home to a thriving network of more than 470 biotechnology companies. A high number of established biotechnology and pharmaceutical players and extensive R&D initiatives being undertaken by them are expected to create a high need for DBS testing for therapeutic drug monitoring applications.
Various international organizations such as the U.S. Food and Drug Administration and the World Health Organization acknowledge the role of DBS cards in this pandemic. For instance, In June 2021, Symbiotic, Inc. was granted EUA by the FDA for a COVID-19 self-collect antibody test. This test can be conducted using ELISA with DBS for detecting COVID-19 antibodies in individuals aged 18 years and older, with collecting the sample in children aged 5 years and older by an adult.
The increase in the adoption of dried blood spot collection cards for therapeutic drug monitoring is a major factor expected to boost market growth in the near future. For instance, in July 2022, a study was conducted by researchers from the University of Washington and Med Biotech Laboratories to assess the feasibility of at-home dried blood spot collection along with PCR as a technique for malaria research. The study is anticipated to impact the therapeutic drug and vaccine studies for malaria. Researchers concluded that at-home dried blood spot collection cards for PCR are acceptable, robust, and feasible techniques.
On the other hand, it has been observed that dried blood spot collection cards are susceptible to cross-contamination or contamination by users, the environment, the equipment, and other collection cards during sample processing. The majority of these concerns can be mitigated by proper care and handling. Prolonged air drying of the conventional dried blood spot collection cards and contamination between samples during blood collection are some major causes of a high proportion of reactive samples.
Dried Blood Spot Collection Cards Market Report Highlights
- The New Born Screening (NBS) segment dominated the market with a revenue share of 25.19% in 2024. Advancements in research technologies to improve newborn screening are a major factor driving the market.
- The Whatman 903 segment dominated the market with a share of 40.57% in 2024 and is anticipated to grow at the fastest growth rate over the forecast period.
- Hospitals and clinics dominated the market with a share of 73.33% in 2024. Hospitals and clinics were key end users of DBS collection cards in 2024, owing to mandatory newborn screening in various regions.
- North America dried blood spot collection cards market dominated the global industry with the largest revenue share of 35.03% in 2024. The dominant share can be attributed to the presence of a large number of manufacturers and well-established childcare facilities in the region.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments
- Competitive Landscape: Explore the market presence of key players worldwide
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
The leading players in the Dried Blood Spot Collection Cards market include:
- QIAGEN
- Perkinelmer
- Roche
- Shimadzu Corporation
- Ahlstrom-Munksjö
- Pall Corporation
- Eastern Business Forms, Inc
- Archimed Life Science Gmbh
- Centogene N.V.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Dried Blood Spot Collection Cards Market Variables, Trends & Scope
Chapter 4. Dried Blood Spot Collection Cards Market: Application Estimates & Trend Analysis
Chapter 5. Dried Blood Spot Collection Cards Market: Card Type Estimates & Trend Analysis
Chapter 6. Dried Blood Spot Collection Cards Market: End-use Estimates & Trend Analysis
Chapter 7. Dried Blood Spot Collection Cards Market: Regional Estimates & Trend Analysis by Product Type, Technology, and End-use
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- QIAGEN
- Perkinelmer
- Roche
- Shimadzu Corporation
- Ahlstrom-Munksjö
- Pall Corporation
- Eastern Business Forms, Inc
- Archimed Life Science Gmbh
- Centogene N.V.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | October 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 399.49 Million |
| Forecasted Market Value ( USD | $ 527.1 Million |
| Compound Annual Growth Rate | 4.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
